ITRM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.145

-42%

-0.100

-28.57%

-0.100

-37.5%

Estimates Revision

The market is revising Downward the revenue expectations for Iterum Therapeutics plc (ITRM) for FY2025, with the revenue forecasts being adjusted by -9.6% over the past three months. During the same period, the stock price has changed by -59.41%.

Revenue Estimates for FY2025

Revise Downward

-9.6%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+11.86%

In Past 3 Month

Stock Price

Go Down

-59.41%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast ITRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITRM is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

Current: 0.000

Low

2.00

Averages

2.00

High

2.00

H.C. Wainwright

initiated

2025-05-08

Reason

H.C. Wainwright

Price Target

2025-05-08

initiated

Reason

H.C. Wainwright assumed coverage of Iterum Therapeutics with a Buy rating and $9 price target. Iterum is a pre-commercial stage company with an FDA approved product, the analyst tells investors in a research note. The firm says the company has the potential to deliver in urinary tract infections and infectious disease.

Valuation Metrics

The current forward P/E ratio for Iterum Therapeutics PLC (ITRM.O) is -0.72, compared to its 5-year average forward P/E of -2.12. For a more detailed relative valuation and DCF analysis to assess Iterum Therapeutics PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.12

Current PE

-0.72

Overvalued PE

0.28

Undervalued PE

-4.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.75

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.31

Undervalued EV/EBITDA

-2.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

394.32

Current PS

2.68

Overvalued PS

2105.51

Undervalued PS

-1316.86

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ITRM News & Events

Events Timeline

No data

News

7.5

2025-12-05Globenewswire

Iterum Expands ORLYNVAH™ Coverage to 25 Million Lives in the U.S.

5.0

2025-11-24NASDAQ.COM

Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading

9.5

2025-11-14NASDAQ.COM

Applied Therapeutics, Omeros, and Others Experience Significant Price Changes After Market Close

People Also Watch

Frequently Asked Questions

What is Iterum Therapeutics PLC (ITRM) stock price today?

The current price of ITRM is 0.328 USD — it has decreased -4.37 % in the last trading day.

What is Iterum Therapeutics PLC (ITRM)'s business?

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

What is the price predicton of ITRM Stock?

What is Iterum Therapeutics PLC (ITRM)'s revenue for the last quarter?

Iterum Therapeutics PLC revenue for the last quarter amounts to 390.00K USD, decreased % YoY.

What is Iterum Therapeutics PLC (ITRM)'s earnings per share (EPS) for the last quarter?

Iterum Therapeutics PLC. EPS for the last quarter amounts to -0.20 USD, decreased -33.33 % YoY.

What changes have occurred in the market's expectations for Iterum Therapeutics PLC (ITRM)'s fundamentals?

How many employees does Iterum Therapeutics PLC (ITRM). have?

Iterum Therapeutics PLC (ITRM) has 9 emplpoyees as of January 10 2026.

What is Iterum Therapeutics PLC (ITRM) market cap?

Today ITRM has the market capitalization of 17.48M USD.